Download PDF
Horm Metab Res 2012; 44(07): 539-542
DOI: 10.1055/s-0032-1311634
Humans, Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Proteinuria in Metastatic Pheochromocytoma is Associated with an Increased Risk of Acute Respiratory Distress Syndrome, Spontaneously or After Therapy with 131I-Meta-iodobenzylguanidine (131I-MIBG)

A. Porzig
1   Department of Medicine, University of California, San Francisco, California, USA
,
K. K. Matthay
2   Department of Pediatrics, University of California, San Francisco, California, USA
,
S. Dubois
2   Department of Pediatrics, University of California, San Francisco, California, USA
,
M. Pampaloni
3   Department of Nuclear Medicine, University of California, San Francisco, California, USA
,
L. Damon
1   Department of Medicine, University of California, San Francisco, California, USA
,
R. Hawkins
3   Department of Nuclear Medicine, University of California, San Francisco, California, USA
,
R. Goldsby
2   Department of Pediatrics, University of California, San Francisco, California, USA
,
F. Hollinger
2   Department of Pediatrics, University of California, San Francisco, California, USA
,
P. Fitzgerald
1   Department of Medicine, University of California, San Francisco, California, USA
› Author Affiliations
Further Information

Publication History

received 01 November 2011

accepted 04 April 2012

Publication Date:
15 May 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Acute Respiratory Distress Syndrome (ARDS) has been reported rarely in pheochromocytoma, occurring spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Our objective was to determine whether proteinuria is associated with an increased risk of ARDS. This was a retrospective analysis of a prospective cohort study of 64 patients with metastatic pheochromocytoma or paraganglioma treated with 131I-MIBG on institutional protocols. Proteinuria was defined as at least one urinalysis positive for at least trace protein within 1 month prior to 131I-MIBG or within 1 month prior to spontaneous ARDS. Proportions were compared using Fisher’s exact test. Urinalyses within the defined time period were available for 48 patients, 8 of whom had proteinuria. Of the 8 patients with proteinuria, 5 developed ARDS: 3 within 10 days following 131I-MIBG, two 6 months following 131I-MIBG. Both patients who developed ARDS 6 months after 131I-MIBG had proteinuria within 1 month before apparently spontaneous ARDS. None of the 40 patients whose urinalyses were all negative for protein developed ARDS. None of the 16 patients with missing urinalyses developed ARDS. Patients with antecedent proteinuria were more likely to develop ARDS than those without proteinuria (63% vs. 0%; p<0.0001). The following variables were not significantly associated with ARDS: 131I-MIBG activities administered, number of 131I-MIBG administrations, age, hypertension, or secretion of catecholamines or metanephrines. In patients with metastatic pheochromocytoma or paraganglioma, proteinuria is associated with ARDS and urine protein should be examined prior to administering 131I-MIBG.

Key words

ARDS - proteinuria - pheochromocytoma - paraganglioma - MIBG
 

  • References

  • 1 Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349
    CrossrefPubMedGoogle Scholar
  • 2 Almog B, Kupferminc MJ, Many A, Lessing JB. Pheochromocytoma in pregnancy – a case report and review of the literature. Acta Obstet Gynecol Scand 2000; 79: 709-711
    PubMedGoogle Scholar
  • 3 Feldman JM. Adult respiratory distress syndrome in a pregnant patient with a pheochromocytoma. J Surg Oncol 1985; 29: 5-7
    CrossrefPubMedGoogle Scholar
  • 4 Golshevsky JR, Karel K, Teale G. Phaeochromocytoma causing acute pulmonary oedema during emergency caesarean section. Anaesth Intensive Care 2007; 35: 423-427
    PubMedGoogle Scholar
  • 5 Hudsmith JG, Thomas CE, Browne DA. Undiagnosed phaeochromocytoma mimicking severe preeclampsia in a pregnant woman at term. Int J Obstet Anesth 2006; 15: 240-245
    CrossrefPubMedGoogle Scholar
  • 6 Ford J, Rosenberg F, Chan N. Pheochromocytoma manifesting with shock presents a clinical paradox: a case report. CMAJ 1997; 157: 923-925
    PubMedGoogle Scholar
  • 7 Case records of the Massachusetts General Hospital . Weekly clinicopathological exercises. Case 45-1989. A 48-year-old woman with acute respiratory failure and a left suprarenal mass. N Engl J Med 1989; 321: 1316-1329
    CrossrefPubMedGoogle Scholar
  • 8 Adjallé R, Plouin PF, Pacak K, Lenhert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009; 41: 687-696
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajis A, Shiboski S, Fitzgerald P. Phase II study of high-dose [131-I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009; 27: 4162-4168
    CrossrefPubMedGoogle Scholar
  • 10 Kirby BD, Ham J, Fairley HB, Benowitz N, Schambelan M. Normotensive pheochromocytoma. Pharmacologic, paraneoplastic and anesthetic considerations. West J Med 1983; 139: 221-225
    PubMedGoogle Scholar
  • 11 Tong AL, Zeng ZP, Li HZ, Yang D, Lu L, Li M. Expression and effect of transforming growth factor-alpha and tumor necrosis factor-alpha in human pheochromocytoma. Ann N Y Acad Sci 2006; 1073: 277-283
    CrossrefPubMedGoogle Scholar
  • 12 Kontogeorgos G, Scheithauer BW, Kovacs K, Horvath E, Melmed S. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells. Endocr Pathol 2002; 13: 197-206
    CrossrefPubMedGoogle Scholar
  • 13 Tokuda H, Hosoi T, Hayasaka K, Okamura K, Yoshimi N, Kozawa O. Overexpression of protein kinase C-delta plays a crucial role in interleukin-6-producing pheochromocytoma presenting with acute inflammatory syndrome: a case report. Horm Metab Res 2009; 41: 333-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Hirabayashi A, Nishiwaki K, Shimada Y, Ishikawa N. Role of neuropeptide Y and its receptor subtypes in neurogenic pulmonary edema. Eur J Pharmacol 1996; 296: 297-305
    CrossrefPubMedGoogle Scholar
  • 15 Cleary S, Phillips JK, Huynh TT, Pacak K, Elkahloun AG, Barb J, Worrell RA, Goldstein DS, Eisenhofer G. Neuropeptide Y expression in phaeochromocytomas: relative absence in tumors from patients with von Hippel-Lindau syndrome. J Endocrinol 2007; 193: 225-233
    CrossrefPubMedGoogle Scholar
  • 16 Taslipinar A, Yaman H, Yilmaz MI, Demirbas S, Saglam M, Taslipinar MY, Agilli M, Kurt YG, Sonmez A, Azai O, Bolu E, Yenicesu M, Kutlu M. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest 2011; 71: 606-612
    CrossrefPubMedGoogle Scholar
  • 17 Yang G, Hamacher J, Gorshkov B, White R, Sridhar S, Verin A, Chakraborty T, Lucas R. The Dual Role of TNF in Pulmonary Edema. J Cardiovasc Dis Res 2010; 1: 29-36
    PubMedGoogle Scholar
  • 18 Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O’Keefe G, Sperry J, Remick D, Tompkins R, Maier RV. Inflammation and the Host Response to Injury Collaborative Research Program. Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock 2010; 34: 46-51
    PubMedGoogle Scholar
  • 19 Koizumi T, Urushihata K, Hanaoka M, Tsushima K, Fujimoto K, Fujii T, Kubo K. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of pulmonary vascular status in patients with chronic obstructive pulmonary disease. Respirology 2010; 15: 1215-1219
    CrossrefPubMedGoogle Scholar
  • 20 van Kroonenburgh M, Mostard R, Voo S. Metaiodobenzylguanidine scintigraphy in pulmonary and cardiac disease. Curr Opin Pulm Med 2010; 16: 511-515
    CrossrefPubMedGoogle Scholar
  • 21 Rassler B, Reissig C, Briest W, Tannapfel A, Zimmer HG. Catecholamine-induced pulmonary edema and pleural effusion in rats – alpha-and beta-adrenergic effects. Respir Physiol Neurobiol 2003; 135: 25-37
    CrossrefPubMedGoogle Scholar
  • 22 Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63: 321-327
    CrossrefPubMedGoogle Scholar
  • 23 White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis 2011; 58: 19-28
    CrossrefPubMedGoogle Scholar